Want to see AU:SPL full AI Analyst Report?

Starpharma Holdings Limited (SPL) Price & Analysis

23 Followers

SPL Stock Chart & Stats

AU$0.38

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.38

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.09 - AU$0.79

Previous CloseN/A

Volume337.59K

Average Volume (3M)724.95K

Market Cap

AU$298.86M

Enterprise ValueAU$281.40M

Total Cash (Recent Filing)AU$18.25M

Total Debt (Recent Filing)AU$790.00K

Price to Earnings (P/E)―

Beta1.50

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding420,928,440

10 Day Avg. Volume366,126

30 Day Avg. Volume724,950

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)1.93

Price to Sales (P/S)7.47

P/FCF Ratio-5.40

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)AU$24.00M

Bulls Say, Bears Say

Bulls Say

Proprietary Dendrimer Technology PlatformA proprietary platform provides durable competitive advantage across multiple end markets. Starpharma’s dendrimer technology supports both in-house product development and licensing, enabling diversified R&D pathways, repeatable collaborations, and scalable IP-based revenue over the medium term.

Positive Revenue Growth TrajectorySustained top-line growth signals commercial traction for products and partner programs. Reliable revenue growth improves negotiating leverage with partners, helps fund ongoing R&D, and provides a foundation to close margin gaps if cost structure and cash conversion trends improve.

Conservative Leverage And Solid Capital StructureLow leverage reduces refinancing and interest-rate risks, preserving financial optionality for R&D investment or strategic deals. A healthier equity ratio supports resilience through development cycles and lessens immediate pressure to raise dilutive capital.

Bears Say

Negative Operating And Free Cash FlowPersistently negative operating and free cash flows are a structural weakness for a biotech commercializing novel tech. Ongoing cash burn forces reliance on external funding or partners, constrains reinvestment, and increases dilution or limits the company’s ability to independently execute longer-term programs.

Persistent Unprofitable Operations And Weak ReturnsContinued negative EBIT and net margins indicate operational inefficiencies or immature commercialization. Negative ROE and weak profitability reduce capacity to generate internal capital, strain investor returns over time, and mean improvement must come from sustained margin expansion or material revenue scale.

Revenue Dependent On Partner Commercialization And MilestonesA material portion of revenue depends on partner milestones and future royalties, creating execution and timing risk. Partner decisions, regulatory approvals, and commercialization timing can make revenues lumpy and uncertain, limiting predictability of long-term cash generation.

Starpharma Holdings Limited News

Starpharma Hits DEP® Milestone, Opens Licensing Path With Radiopharm

Starpharma Holdings Limited ( ($AU:SPL) ) has provided an announcement. Starpharma has reached a key milestone in its...

2d ago

Starpharma Wins FDA Backing for DEP HER2 Trial as Partnerships and Product Sales Advance

Starpharma Holdings Limited ( ($AU:SPL) ) has provided an update. Starpharma reported strong operational momentum in the March...

2M ago

Starpharma Secures FDA Backing for DEP HER2 First-in-Human Trial Pathway

Starpharma Holdings Limited ( ($AU:SPL) ) has issued an update. Starpharma has received positive guidance from the U.S....

2M ago

Starpharma Seeks ASX Quotation for Over 1 Million New Shares

An update from Starpharma Holdings Limited ( ($AU:SPL) ) is now available. Starpharma Holdings Limited has applied to...

3M ago

UBS Group Ceases to Be Substantial Shareholder in Starpharma

Starpharma Holdings Limited ( ($AU:SPL) ) just unveiled an update. UBS Group AG and its related bodies corporate...

4M ago

Starpharma Ramps Up DEP® Partnerships and Radiopharma Pipeline as Viraleze™ Sales Surge

Starpharma Holdings Limited ( ($AU:SPL) ) has issued an announcement. Starpharma reported a highly active second quarter of...

5M ago

Starpharma Seeks ASX Quotation for 1.69 Million New Ordinary Shares

The latest update is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited has applied to...

6M ago

Starpharma Announces Lapse of 381,810 Performance Rights

Starpharma Holdings Limited ( ($AU:SPL) ) just unveiled an update. Starpharma Holdings Limited has notified the market that...

6M ago

Starpharma CEO Receives New Performance Rights

Starpharma Holdings Limited ( ($AU:SPL) ) has provided an announcement. Starpharma Holdings Limited announced a change in the...

7M ago

Starpharma Issues Unquoted Securities to Boost Employee Incentives

The latest update is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited has announced the...

7M ago

SPL FAQ

What was Starpharma Holdings Limited’s price range in the past 12 months?

Starpharma Holdings Limited lowest share price was AU$0.09 and its highest was AU$0.79 in the past 12 months.

What is Starpharma Holdings Limited’s market cap?

Starpharma Holdings Limited’s market cap is AU$298.86M.

When is Starpharma Holdings Limited’s upcoming earnings report date?

Starpharma Holdings Limited’s upcoming earnings report date is Aug 26, 2026 which is in 53 days.

How were Starpharma Holdings Limited’s earnings last quarter?

Starpharma Holdings Limited released its earnings results on Feb 17, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.

Is Starpharma Holdings Limited overvalued?

According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Starpharma Holdings Limited pay dividends?

Starpharma Holdings Limited does not currently pay dividends.

What is Starpharma Holdings Limited’s EPS estimate?

Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Starpharma Holdings Limited have?

Starpharma Holdings Limited has 420,928,440 shares outstanding.

What happened to Starpharma Holdings Limited’s price movement after its last earnings report?

Starpharma Holdings Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.042%.

Which hedge fund is a major shareholder of Starpharma Holdings Limited?

Currently, no hedge funds are holding shares in AU:SPL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Starpharma Holdings Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-15.96%

Trailing 12-Months

Asset Growth

-4.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Starpharma Holdings Limited

Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.